Adderall XR Cost in New Jersey 2026

What Does Adderall XR Actually Cost in New Jersey Right Now?

The sticker price and the street price are very different numbers in New Jersey. The manufacturer list price for brand-name or authorized generic Adderall XR sits at approximately $260 per month in 2026, but almost no cash-paying patient pays that figure. Across New Jersey retail pharmacies, the average cash-pay price using a discount card lands near $30 per month for a 30-capsule supply of generic mixed amphetamine salts extended-release.

That gap exists for two reasons. First, multiple generic manufacturers compete on price for mixed amphetamine salts XR, pushing the actual acquisition cost for pharmacies well below the brand-list figure. Second, free third-party discount programs such as GoodRx, RxSaver, and NeedyMeds compress retail margins further when applied at the point of sale.

Prices still vary meaningfully by pharmacy chain and zip code within New Jersey. A 20 mg, 30-capsule supply in Newark may price differently at CVS than at an independent pharmacy in Montclair. Running your specific dose through GoodRx or Blink Health before filling the prescription takes less than two minutes and has saved New Jersey patients between $10 and $60 per fill in documented comparisons. The FDA label for Adderall XR confirms that extended-release mixed amphetamine salts are bioequivalent to the branded product when substituted generically, so brand loyalty carries no clinical rationale for most patients.

Dose size also changes the math. Capsule sizes range from 5 mg to 30 mg, and pharmacies generally price higher-strength capsules only marginally more than lower-strength ones. A patient on 25 mg once daily pays nearly the same cash price as a patient on 10 mg, meaning titration decisions should rest on clinical response, not cost anxiety.

How NJ Medicaid Covers Adderall XR in 2026

New Jersey Medicaid (NJ FamilyCare) covers Adderall XR with prior authorization. Approval is straightforward for most patients who carry a documented ADHD diagnosis and have had a face-to-face or telehealth clinical evaluation.

The prior authorization (PA) process under NJ FamilyCare typically requires the prescribing clinician to submit documentation showing a DSM-5-TR confirmed ADHD diagnosis, the patient's age and weight, any prior stimulant trials if applicable, and confirmation that the prescriber holds a valid New Jersey DEA registration for Schedule II substances. For children aged 6 to 12, the PA form additionally asks for documentation of a school-based or behavioral assessment. Processing time runs 3 to 5 business days for standard requests, though urgent PA pathways exist for patients who are destabilizing off medication.

Once approved, NJ Medicaid enrollees pay a nominal copayment, often $1 to $3 per fill for generic formulations, effectively eliminating out-of-pocket cost as a barrier to treatment. Dual-eligible patients (Medicare and Medicaid) route coverage through Part D, where the same PA logic applies but the formulary and cost-sharing structure differs by plan.

The National Institute of Mental Health estimates that roughly 9.4% of U.S. children aged 2 to 17 have received an ADHD diagnosis, underscoring the scale of this coverage question for state Medicaid programs. New Jersey's decision to require only PA rather than step-therapy or quantity limits places it among the more accessible state Medicaid programs for stimulant coverage nationally.

Is Compounded Mixed Amphetamine Salts Legal in New Jersey?

Yes. Licensed 503A compounding pharmacies in New Jersey may legally prepare compounded mixed amphetamine salts for individual patients when a valid prescription from a licensed prescriber is presented and a legitimate medical need exists. The 503A designation refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs patient-specific compounding at state-licensed pharmacies.

This matters for two groups of patients. First, patients who need a dose form not commercially available, such as a liquid suspension for a child who cannot swallow capsules or a specific extended-release profile not matched by any available generic. Second, patients who are cost-sensitive, because some 503A pharmacies offer compounded mixed amphetamine salts at lower out-of-pocket cost than commercially manufactured generics, particularly during periods of supply shortage.

However, several legal constraints apply. The prescription must specify an individual patient. The compounding pharmacy must hold both a New Jersey Board of Pharmacy license and a valid DEA Schedule II controlled substance registration. The pharmacist cannot compound commercially available products in bulk without a patient-specific prescription. The FDA's guidance on 503A compounding makes clear that compounded preparations are not FDA-approved and may differ in potency or bioavailability from manufactured products, a clinical point prescribers should communicate to patients.

During the 2022 to 2024 nationwide Adderall shortage, many New Jersey patients turned to 503A compounders as a supply-chain workaround. The FDA's drug shortage database tracked mixed amphetamine salts among the most persistently short medications in that period. Compounding provided continuity of care for patients who would otherwise have gone untreated for weeks.

One clinical caveat: because compounded products are not subject to FDA bioequivalence testing, switching between a manufactured generic and a compounded formulation should be treated as a dose adjustment, not a simple substitution. Clinicians should schedule a follow-up within 4 weeks of any such switch.

Which Insurance Plans Cover Adderall XR in New Jersey?

Most commercial insurance plans operating in New Jersey, including Horizon Blue Cross Blue Shield of NJ, Aetna, Cigna, and UnitedHealthcare, place generic mixed amphetamine salts XR on Tier 2 or Tier 3 of their formularies. Tier 2 typically means a $15 to $45 copayment per 30-day supply after the deductible is met. Tier 3 copayments in New Jersey employer-sponsored plans run $45 to $90 per fill.

Brand-name Adderall XR (manufactured by Teva) is rarely covered preferentially over generics on commercial plans in 2026. When a prescriber writes "brand medically necessary," plans usually require a separate PA demonstrating documented clinical failure or adverse reaction to all available generics before approving brand coverage.

The Affordable Care Act requires all non-grandfathered individual and small-group plans sold on the New Jersey marketplace (GetCoveredNJ) to cover mental health and substance use disorder benefits at parity with medical benefits. ADHD medications prescribed for a covered diagnosis therefore cannot face higher cost-sharing than comparable medical treatments under that parity requirement. Patients who believe their insurer is applying more restrictive limits than allowed may file a complaint with the New Jersey Department of Banking and Insurance.

For high-deductible health plans, the full deductible must be met before cost-sharing kicks in. A patient on a $2,000 deductible HDHP who fills Adderall XR in January pays the pharmacy's negotiated rate, often $40 to $80 per fill for generic, until the deductible clears. Pairing a discount card (GoodRx) with an HDHP is occasionally cheaper than running through insurance before the deductible is satisfied, though this creates an HSA compliance issue. Patients should verify with their benefits administrator before bypassing insurance.

Savings Programs and Discount Cards That Work in New Jersey

Several programs reduce Adderall XR cost for New Jersey residents regardless of insurance status. The most accessible tools in 2026 are outlined below.

GoodRx and similar discount platforms. GoodRx operates as a prescription benefit manager that negotiates group rates. In New Jersey, GoodRx prices for 30 capsules of generic mixed amphetamine salts XR (20 mg) have been documented as low as $18 to $35 depending on the pharmacy and exact formulation. The card is free, requires no enrollment, and cannot be combined with insurance at the point of sale.

NeedyMeds Patient Assistance. NeedyMeds maintains a database of manufacturer patient assistance programs (PAPs). Teva, the primary Adderall XR manufacturer, has historically offered a patient assistance program for uninsured patients below 200% of the federal poverty level. Income thresholds and availability change annually; patients should check NeedyMeds.org for current eligibility.

340B Program. Federally Qualified Health Centers (FQHCs) and other 340B-covered entities in New Jersey can dispense Adderall XR at 340B pricing. The discount is passed to uninsured or underinsured patients. Newark Community Health Centers and similar organizations in Camden and Trenton participate in 340B. A patient must receive care at the FQHC to access 340B pricing there.

New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD). PAAD provides drug cost assistance to New Jersey residents aged 65 and older or permanently disabled who meet income thresholds. Schedule II medications are covered under PAAD with appropriate documentation. The program is administered by the NJ Division of Aging Services.

The HealthRX Cost Decision Framework for New Jersey patients works as follows. If you have NJ Medicaid: submit the PA and pay the Medicaid copay, which is likely less than $5. If you have commercial insurance: compare your Tier 2 or Tier 3 copay against the GoodRx cash price before every fill, and use whichever is cheaper. If you are uninsured and earn below 200% of the federal poverty level: apply for the Teva PAP or seek care at a 340B FQHC. If you are uninsured and above that income threshold: GoodRx cash pay at a high-volume pharmacy in your county is almost always the fastest path to the $30 price point. If supply is short: contact a licensed 503A compounding pharmacy in New Jersey for a patient-specific compounded preparation with a valid Schedule II prescription.

The Clinical Evidence Behind Mixed Amphetamine Salts

Understanding the cost picture means less without context on what the medication does. Mixed amphetamine salts XR is a central nervous system stimulant that releases amphetamine in a biphasic pattern over 8 to 12 hours, providing morning and afternoon coverage from a single capsule.

The Multimodal Treatment Study of ADHD (MTA study, N=579, published in Archives of General Psychiatry, 1999) remains the largest long-term randomized trial in childhood ADHD. Carefully titrated stimulant medication produced significantly greater reductions in ADHD symptom scores than behavioral treatment alone or community care at 14 months, with a combined medication-plus-behavioral-treatment arm showing the broadest improvement across outcomes [1]. The MTA investigators concluded that "medication management was superior to behavioral treatment and to community care" for core ADHD symptoms, a finding that still anchors current prescribing guidelines.

The American Academy of Pediatrics 2019 Clinical Practice Guideline for ADHD (Pediatrics, 2019) recommends stimulant medication as first-line pharmacotherapy for children aged 6 and older with ADHD [2]. The guideline specifically states that "for children ages 6 years and older... approved medications for ADHD should be prescribed." Mixed amphetamine salts, including the extended-release formulation, appear on all major U.S. formularies under this recommendation.

For adults, a 2020 meta-analysis published in The Lancet Psychiatry (N=20,861 participants across 133 trials) found that amphetamines produced the largest effect size for ADHD symptom reduction in adults (standardized mean difference 0.79 to 95% CI 0.62 to 0.97) compared with other stimulant and non-stimulant agents [3]. Effect sizes of this magnitude are clinically substantial and help explain why mixed amphetamine salts remain the most prescribed ADHD medication class in the United States.

Adverse effects relevant to prescribing decisions include appetite suppression, insomnia, elevated blood pressure, and elevated heart rate. The FDA prescribing information carries a black box warning regarding the potential for abuse and dependence, which is the regulatory basis for the Schedule II classification and the prescription requirements that govern New Jersey dispensing.

Telehealth Prescribing of Adderall XR in New Jersey

New Jersey permits telehealth prescribing of controlled substances, including Schedule II stimulants, under conditions established by state law and applicable federal regulations.

The federal Ryan Haight Online Pharmacy Consumer Protection Act of 2008 originally required an in-person medical evaluation before any controlled substance could be prescribed via telemedicine. The DEA's COVID-era telemedicine exceptions, extended through 2025 and under proposed rulemaking for 2026, allow DEA-registered clinicians to prescribe Schedule II medications via audio-video telehealth without a prior in-person visit, provided the patient is in a state where telehealth prescribing is authorized and the clinician meets all DEA registration requirements.

In New Jersey, both the prescriber and the patient must be located within the United States during the encounter. The prescriber must hold a valid New Jersey medical license and a DEA Schedule II registration. The patient must complete a full psychiatric or clinical evaluation during the telehealth session, with documentation of DSM-5-TR criteria met for ADHD, review of cardiovascular history, blood pressure screening, and a controlled substance agreement signed prior to or during the first prescription.

HealthRX's clinical team follows this protocol for all New Jersey telehealth ADHD evaluations. Once a prescription is issued, it is transmitted electronically to a New Jersey pharmacy of the patient's choice or to a licensed 503A compounding pharmacy if a non-commercially-available formulation is indicated. Controlled substance prescriptions in New Jersey must comply with the New Jersey Prescription Monitoring Program (NJPMP), and prescribers are required to query the NJPMP before issuing each Schedule II prescription.

The New Jersey Division of Consumer Affairs maintains current telehealth prescribing requirements for licensed practitioners and updates them as DEA rulemaking evolves.

What to Expect at the Pharmacy Counter in New Jersey

Schedule II prescriptions in New Jersey carry specific dispensing rules that affect patient experience at the pharmacy.

New Jersey law requires a written or electronic Schedule II prescription. Oral (phone) prescriptions for Schedule II medications are not permitted except in genuine emergencies, and even then a written prescription must follow within 7 days. Electronic prescriptions for controlled substances (EPCS) are permitted and now standard at most New Jersey pharmacies, which reduces the lag between a telehealth visit and dispensing.

Quantity limits apply. New Jersey pharmacies may not dispense more than a 30-day supply of a Schedule II medication per prescription. Prescribers cannot post-date or issue multiple prescriptions to cover more than 30 days at one time under New Jersey law, though the DEA does allow prescribers to issue multiple dated prescriptions to be filled sequentially in some circumstances. Patients who receive 90-day supplies of other medications through mail-order pharmacies cannot do the same with Adderall XR.

Refill rules are strict. Schedule II medications have zero refills. A new prescription is required for every 30-day supply. This is a federal DEA requirement, not a New Jersey-specific rule, but it means ADHD patients must maintain consistent contact with their prescriber. At HealthRX, follow-up appointments are built into the care plan at 30-day intervals for the first three months of treatment, then every 90 days once the dose is stable.

Patients should bring photo identification to the pharmacy. Many New Jersey pharmacies require ID verification for Schedule II dispensing and log the dispensing event in a bound record book or electronic system linked to the NJPMP.

How Supply Shortages Affect New Jersey Pricing and Access

Supply chain disruptions have affected Adderall XR availability intermittently since late 2022. The FDA drug shortage database listed mixed amphetamine salts among the most frequently shorted medications in 2022 and 2023, with partial recovery through 2024 and 2025.

During shortage periods, New Jersey patients have experienced three specific problems. First, pharmacies running low on stock sometimes redirect patients to the brand-name product, which is priced at $260 per month and not always covered by insurance without PA. Second, some manufacturers limit per-pharmacy allocation volumes, forcing patients to call multiple pharmacies to locate stock. Third, compounding pharmacies, seeing increased demand, occasionally face their own API (active pharmaceutical ingredient) supply constraints, as bulk pharmaceutical-grade amphetamine salts are subject to DEA aggregate production quotas set annually.

The DEA raised its aggregate production quota for amphetamine in 2024 by approximately 15% to address shortage conditions, per the DEA's published Federal Register notice. Whether that adjustment fully resolves supply constraints through 2026 depends on manufacturing output at the three primary API suppliers for the U.S. market.

New Jersey patients who encounter stock shortages have three practical options: call ahead to 5 to 8 pharmacies in their area using the GoodRx pharmacy locator (which shows real-time stock in some markets), ask their prescriber to authorize a compounded preparation at a licensed 503A pharmacy, or request a therapeutic substitution to an equivalent stimulant such as lisdexamfetamine (Vyvanse) or methylphenidate extended-release if clinically appropriate.

A 30 mg daily dose of mixed amphetamine salts XR is not clinically equivalent to any fixed dose of lisdexamfetamine; conversion requires prescriber judgment, not a simple milligram-to-milligram switch. Patients should not attempt dose conversions independently.